Cardlytics CDLX 深 沪
等待开盘 10-15 09:30:00 美东时间
2.13
-0.030
-1.39%
华盛通- 最 高2.22
- 今 开2.16
- 成交量 6.69万股
- 最 低 2.05
- 昨 收 2.16
- 总市值 1254.30万
- 52周最高 20.90
- 市盈率 静 --
- 换手率 1.14%
- 52周最低 1.83
- 委 比 -53.37%
- 总股本 588.87万
- 历史最高 1614.70
- 量 比 0.55
- 振 幅 7.87%
- 历史最低 2.05
- 每 手 1
- 风险率 4.48%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Cardlytics Settles Bridg-Related Indemnification Dispute Agreement
Cardlytics ( ($CDLX) ) has provided an announcement. Cardlytics has disclosed t...
09-11 21:28
Cardlytics Reaches $6.4M Settlement Agreement With Former Bridg CEO Amit Jain
https://www.sec.gov/ix?doc=/Archives/edgar/data/1666071/000162828026061459/cdlx-20260904.htm
09-11 21:05
Cardlytics Sees Q3 Sales $34.000M-$39.000M vs $38.594M Est
Cardlytics (NASDAQ:CDLX) sees Q3 sales of $34.000 million-$39.000 million vs $38.594 million analyst estimate.
08-06 04:04
Cardlytics将于8月5日发布第二季度财报
广告科技公司Cardlytics（纳斯达克代码：CDLX）宣布，将于2026年8月5日（周三）美股盘后公布第二季度财务业绩。公司将于当天下午5点（美国东部时...
07-21 21:42
Cardlytics Q1 Adj. EPS $(0.11) Beats $(0.21) Estimate, Sales $34.319M Miss $37.200M Estimate
Cardlytics (NASDAQ:CDLX) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.21) by 47.62 percent. This is a 47.62 percent increase over losses of $(0.21) per share from the
05-08 04:04
美股夜盘 | PMGC Holdings Inc.涨88.02%，MicroCloud Hologram Inc. - Ordinary Shares涨22.51%
PMGC Holdings Inc.涨88.02%；MicroCloud Hologram Inc. - Ordinary Shares涨22.51%；MOMENTUS INC涨19.07%
03-30 13:01
Why Faraday Future Intelligent Electric Shares Are Trading Higher By Around 55%; Here Are 20 Stocks Moving Premarket
Faraday Future Intelligent Electric shares up 54.8% in pre-market trading after SEC investigation ends with no penalties or enforcement actions.
03-23 18:34
Earnings Scheduled For March 4, 2026
Companies Reporting Before The Bell • Dingdong (Cayman) (NYSE:DDL) is estimated...
03-04 19:11
Celldex Presents Additional Results From Phase 2 Clinical Sturies Of Barzolvolimab In Chronic Spontaneous Urticaria And Cold Urticaria And Symptomatic Dermographism At 2026 Allergy, Asthma & Immunology's Annual Meeting
Celldex (NASDAQ:CLDX) presented additional positive data from the completed Phase 2 clinical trials of barzolvolimab in chronic spontaneous urticaria (CSU) and cold urticaria (ColdU) and symptomatic dermographism (SD).
02-28 03:49
12 Communication Services Stocks Moving In Friday's Intraday Session
Gainers GCL Global Holdings (NASDAQ:GCL) stock rose 10.2% to $0.68 during Frid...
02-21 01:05
